Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2013; 19(33): 5485-5492
Published online Sep 7, 2013. doi: 10.3748/wjg.v19.i33.5485
Published online Sep 7, 2013. doi: 10.3748/wjg.v19.i33.5485
Figure 4 Evaluation of apoptosis by terminal transferase dUTP nick-end labeling and DNA ladder assays in pancreatic cancer MIA-PaCa-2 cells after propofol pretreatment.
A: Sensitization of pancreatic tumor MIA-PaCa-2 cells to propofol- and/or gemcitabine-induced apoptosis measured by terminal transferase dUTP nick-end labeling (TUNEL) assay after 24 h of pretreatment with propofol (50 μmol/mL), gemcitabine (0-100 μmol/L), or propofol and gemcitabine combined for 72 h. Increased apoptosis was evident in the combination treatment group relative to individual treatment groups. aP < 0.05 vs propofol and gemcitabine combined group; B: Representative TUNEL image of MIA-PaCa-2 cells pretreated with propofol (50 μmol/mL) for 24 h followed by coincubation with gemcitabine (50 μmol/L) for 72 h; C: Representative DNA ladder image of MIA-PaCa-2 cells pretreated with propofol (50 μmol/mL) for 24 h followed by coincubation with gemcitabine (50 μmol/L) for 72 h.
-
Citation: Du QH, Xu YB, Zhang MY, Yun P, He CY. Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells
in vitro by inhibition of nuclear factor-κB activity. World J Gastroenterol 2013; 19(33): 5485-5492 - URL: https://www.wjgnet.com/1007-9327/full/v19/i33/5485.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i33.5485